These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37008324)

  • 1. Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction.
    Yeh JS; Chen WT; Tomlinson B; Tam WC; Chien LN
    Front Cardiovasc Med; 2023; 10():1143509. PubMed ID: 37008324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: Data from the praise registry.
    D'Ascenzo F; Elia E; de Filippo O; Manai R; Breviario S; Bruno F; Iannaccone M; Wańha W; Bianco M; Patti G; Raposeiras-Roubin S; Abu-Assi E; Bo M; De Ferrari GM; Conrotto F;
    Int J Cardiol; 2022 Apr; 353():9-14. PubMed ID: 35090983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
    JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
    Kim CJ; Park MW; Kim MC; Choo EH; Hwang BH; Lee KY; Choi YS; Kim HY; Yoo KD; Jeon DS; Shin ES; Jeong YH; Seung KB; Jeong MH; Yim HW; Ahn Y; Chang K;
    Lancet; 2021 Oct; 398(10308):1305-1316. PubMed ID: 34627490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
    Xu S; Liang Y; Chen Y; Gao H; Tan Z; Wang Q; Liu Y; Zhu B; Tao F; Wang Q; Zhao S; Yang L; Zhang Y; Wang Z; Han P; Chen Y; Zhang A; Li C; Lian K
    Drugs Aging; 2022 Sep; 39(9):695-703. PubMed ID: 35995912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
    Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors.
    Byun S; Lee SN; Lim S; Choo EH; Choi IJ; Kim CJ; Moon D; Park MW; Park CS; Ahn Y; Jeong MH; Chang K
    J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry.
    Xi Z; Qiu Z; Li J; Qiu H; Guo T; Wang Y; Zheng J; Gao Y; Gao R
    Platelets; 2022 Nov; 33(8):1270-1278. PubMed ID: 36050819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
    Kim Y; Jeong MH; An M; Cho K; Hong Y; Kim J; Ahn Y
    PLoS One; 2023; 18(2):e0278993. PubMed ID: 36821598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Bleeding and Ischemic Events in Asian Patients on P2Y12-Inhibitors After Percutaneous Coronary Intervention: A National Claims Data Analysis.
    Lee Y; Lim YH; Park Y; Shin J
    Adv Ther; 2021 Jan; 38(1):562-578. PubMed ID: 33179207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of de-escalation of P2Y12 receptor inhibitor therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: A nationwide cohort study.
    Yeh JS; Hsu CY; Huang CY; Chen WT; Hsieh YC; Chien LN
    PLoS One; 2021; 16(1):e0246029. PubMed ID: 33493236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
    O'Donoghue ML; Murphy SA; Sabatine MS
    Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
    Choo EH; Choi IJ; Lim S; Moon D; Kim CJ; Park MW; Kim MC; Hwang BH; Lee KY; Seok Choi Y; Kim HY; Yoo KD; Jeon DS; Ahn Y; Chang K;
    Circ Cardiovasc Interv; 2022 Dec; 15(12):e012157. PubMed ID: 36382599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health.
    Ahn JH; Ahn Y; Jeong MH; Kim JH; Hong YJ; Sim DS; Kim MC; Hwang JY; Yoon JH; Seong IW; Hur SH; Oh SK;
    J Cardiol; 2020 May; 75(5):478-484. PubMed ID: 31859138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials.
    Abusnina W; Al-Abdouh A; Bizanti A; Gill G; Houssien A; Alshebani Y; Kanmanthareddy A; Dahal K
    Cardiovasc Revasc Med; 2022 May; 38():54-60. PubMed ID: 34384690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries.
    Peyracchia M; Saglietto A; Biolè C; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Wilton SB; Velicki L; Xanthopoulou I; Correia L; Rognoni A; Fabrizio U; Nuñez-Gil I; Montabone A; Taha S; Fujii T; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Kawaji T; Blanco PF; Garay A; Quadri G; Queija BC; Huczek Z; Paz RC; González-Juanatey JR; Fernández MC; Nie SP; D'Amico M; Pousa IM; Kawashiri MA; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca A; Cequier A; Alexopoulos D; Iñiguez-Romo A; Grossomarra W; Usmiani T; Rinaldi M; D'Ascenzo F
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):259-269. PubMed ID: 31586336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.
    Li D; Sun Y; Ye X; Li L; Chen Y; Wang D
    Adv Ther; 2022 Jan; 39(1):754-766. PubMed ID: 34904209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study.
    Yu XF; Chen HW; Xu J; Xu QZ; Zhang XH; Li BB; Xu BL; Ma LK
    Front Cardiovasc Med; 2022; 9():932054. PubMed ID: 36386368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.